Looking Ahead to 2022 With the Editors of AJMC®

Combination therapy with enfortumab vedotin and pembrolizumab significantly reduces progression and mortality risk of muscle invasive bladder cancer in first-line treatment.

The founder and President of Phesi addresses the need for streamlining clinical trial data as GLP-1 RA therapies are being used to treat multiple diseases.

Researchers identify FGFR4, FLT1, and WNT5A as key biomarkers and suggest dovitinib and nintedanib as new targeted therapies for colorectal cancer.

Laxmi Patel of Savista discusses how the Budget Reconciliation Act could widen Medicaid coverage gaps and strain hospitals across states.

Metallomic correlations suggest environmental and metabolic metals act together to accelerate renal damage.

Integrated data suggest higher tryptophan activity is associated with reduced inflammation and improved outcomes in RA.